Adjuvant Chemotherapy in Node Negative Breast Cancer
Author Information
Author(s): J.M. Morrison, A. Howell, K.A. Kelly, R.J. Grieve, L.J. Monypenny, R.A. Walker, J.A.H. Waterhouse
Primary Institution: Selly Oak Hospital, Birmingham, UK
Hypothesis
Patients with node negative disease would benefit from chemotherapy.
Conclusion
The study found no significant benefit of adjuvant chemotherapy on relapse-free or overall survival in patients with node negative breast cancer.
Supporting Evidence
- 90% of patients received eight cycles of chemotherapy with no dose reduction.
- At 5 years, the relapse-free survival was 73% in the treated group and 71% in the control group.
- There was a significant difference in the distribution of metastases between treated and control groups.
Takeaway
The study tested if chemotherapy helps women with early-stage breast cancer that hasn't spread to lymph nodes, but it didn't show any benefits.
Methodology
Patients were randomized to receive either chemotherapy or no treatment after mastectomy, with follow-up assessments for survival and recurrence.
Limitations
The study may not have included enough high-risk patients to detect a significant benefit from chemotherapy.
Participant Demographics
Patients were women with node negative breast cancer, aged below 65.
Statistical Information
P-Value
0.47
Confidence Interval
95% CI 67-78%
Statistical Significance
p=0.47
Want to read the original?
Access the complete publication on the publisher's website